Global Yeast Infection Treatment Market Growth Opportunities, And Future Prospects (2024-2033)

"The new report published by The Business Research Company, titled "" Yeast Infection Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the yeast infection treatment market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The yeast infection treatment market size is expected to see strong growth in the next few years. It will grow to $5.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13958&type=smp

Autoimmune Disease Surge Fuels Growth In Yeast Infection Treatment Market
The rise in the prevalence of autoimmune disease is expected to propel the growth of the yeast infection treatment market going forward. Autoimmune disease is a condition where the immune system mistakenly attacks healthy cells, tissues, and organs, weakening bodily function and potentially becoming life-threatening. Yeast infection treatment are used in managing and preventing the complications of autoimmune disease by addressing recurrent yeast infections, which are linked to certain autoimmune syndromes, and by potentially modulating the immune response through the management of fungal infections in patients with autoimmune conditions. For instance, in March 2023, according to the National Institutes of Health, a US-based federal agency for conducting and supporting medical research, an estimated 8.4 million people globally were predicted to have type 1 diabetes (T1DM) in 2021, with 500,000 new cases reported in that year. Further, the estimated population with T1DM is expected to be between 13.5 and 17.4 million by 2040. Therefore, the rise in the prevalence of autoimmune diseases is driving the growth of the yeast infection treatment market.

Increasing Focus On Introducing Innovative Oral Antifungal Solutions To Revolutionize Yeast Infection Treatment
Major companies operating in the yeast infection treatment market are focusing on introducing innovative solutions or medications, such as non-azole oral antifungals, to gain a competitive edge in the market. A non-azole oral antifungal is a medication taken by mouth that fights fungal infections but does not belong to the azole class of antifungals. For instance, in December 2022, SCYNEXIS, a US-based biotechnology company, announced approval from the United States Food and Drug Administration (FDA), a US-based federal agency, for the second indication for BREXAFEMME (ibrexafungerp tablets). This is an innovative non-azole oral antifungal, the first FDA-approved therapy used for both the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and the reduction in the incidence of recurrent VVC. It offers a novel alternative with broad-spectrum activity, impacting the dynamics of the yeast infection treatment market and addressing limited options for patients with recurrent VVC. The recommended dosage of BREXAFEMME for the treatment of VVC is 300 mg (two 150 mg tablets), given one day at a time, about 12 hours apart, for a total of 600 mg (four 150 mg tablets) every day.

The yeast infection treatment market covered in this report is segmented -

1) By Type: Powders, Creams Or Ointments, Tablets Or Capsules, Other Types
2) By Treatment: Medical Treatment, Surgery
3) By Indication: Genital Candidiasis, Invasive Candidiasis, Oropharyngeal Or Esophageal Candidiasis (Thrush), Other Indications
4) By Route Of Administration: Oral, Topical, IV (Intravenous) Or IM (Intramuscular), Other Routes Of Administration
5) By Application: Retail Pharmacies Or Drug Stores, Hospital Pharmacies, Specialty Stores, Online Sales, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13958&type=discount

Major companies operating in the yeast infection treatment market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Thermo Fisher Scientific Inc., Abbott Laboratories, AstraZeneca PLC, Bayer AG, Astellas Pharma Inc., Torrent Pharmaceuticals, Catalent Inc., bioMérieux SA, Cipla, Bruker Corporation, Brundavan Laboratories Private Limited, Glenmark Pharmaceuticals Ltd, Zydus Lifesciences, Prestige Consumer Healthcare Inc., CordenPharma International, Synmedic Laboratories, Basilea Pharmaceutica AG, Jubilant Pharmova Limited, Curia Global Inc., Synexis LLC, Manus Aktteva Biopharma LLP

Contents of the report:
1. Executive Summary
2. Yeast Infection Treatment Market Report Structure
3. Yeast Infection Treatment Market Trends And Strategies
4. Yeast Infection Treatment Market - Macro Economic Scenario
5. Yeast Infection Treatment Market Size And Growth
…..
27. Yeast Infection Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/yeast-infection-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.